

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:01:50 ON 03 FEB 2003

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:02:00 ON 03 FEB 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3
 DICTIONARY FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
 Uploading 09815362.str

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:02:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2113 TO ITERATE

47.3% PROCESSED 1000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 39504 TO 45016
PROJECTED ANSWERS: 119 TO 641

L2 9 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:02:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41513 TO ITERATE

100.0% PROCESSED 41513 ITERATIONS 417 ANSWERS
SEARCH TIME: 00.00.01

L3 417 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 07:02:22 ON 03 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 2 Feb 2003 (20030202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3


L4 33 L3

=> d ibib abs hitstr 1-33

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:754359 CAPLUS
 DOCUMENT NUMBER: 137:263032
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.; Gomez, Dario G.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
US 2003023098	A1	20030130	US 2001-815362	20010321
<p>PRIORITY APPLN. INFO.: US 2001-815362 A 20010321 US 1997-985347 B2 19971204 US 1998-205597 B2 19981204 US 1999-329752 B2 19990610</p>				

OTHER SOURCE(S): MARPAT 137:263032
 GI




AB Comps. (shown as I), which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such comps. In I, each x is independently 1 or 2; each R1 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2. Each R2 and each R3 are


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 226571-36-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride 226571-37-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 226571-02-4 CAPLUS

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H; C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2; or an R2 and an R3 together condense to form a satd., partly satd., or unsatd. ring structure having the formula -[C(R6)p]q-Xs-[C(R6)p]r-Xt-[C(R6)p]u where each R6 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5. Each X is independently O, S, or N and s is 0 or 1; provided that q + r + u + s + t < 6. Y is O; S; N; -[C(R7)z]s-, where each R7 is independently as previously defined for R1, each z is independently 1-2, and s is 1-3; -CH; -CH:CH-; or Y1CH2, where Y1 is O, N, or S; and the dotted lines in I are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsatd., and that if Y is O, N or S, the ring including Y contains at least one said double bond. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed comps. relative to brimonidine/oxymetazoline are tabulated. Although the methods of prepn. are not claimed, .apprx.100 example prepn. are included.
 IT 157058-47-4P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)
 RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-44-1P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- 157058-52-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 157058-55-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- 226570-89-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride 226571-02-4P, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- 226571-05-7P, 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- 226571-13-7P, 1H-Imidazole, 4-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-14-8P, 1H-Imidazole, 4-[[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-25-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- 226571-26-2P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- 226571-35-3P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]-

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:576071 CAPLUS
DOCUMENT NUMBER: 137:262610
TITLE: Highly Enantioselective Reformatskii Reaction of Ketones: Chelation-Assisted Enantioface Discrimination
AUTHOR(S): Ojida, Akio; Yamano, Toru; Taya, Naohiro; Tasaka, Akihiro
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan
SOURCE: Organic Letters (2002), 4(18), 3051-3054
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Highly enantioselective Reformatskii reaction of ketones was accomplished using cinchona alkaloids as chiral ligands. Chelation with the sp²-nitrogen adjacent to the reactive carbonyl center contributed to the enantioface discrimination for the high enantioselectivities.

IT 463304-60-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
RN 463304-60-1 CAPLUS
CN Methanone, 2-naphthalenyl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




IT 463304-61-2P 463304-63-4P 463304-73-6P
463304-74-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
RN 463304-61-2 CAPLUS
CN 1H-Imidazole-4-propanoic acid, .beta.-hydroxy-.beta.-2-naphthalenyl-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 463304-63-4 CAPLUS

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 226571-57-9P, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)


RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(1H-imidazol-4-yl)-3-(2-naphthalenyl)-1-oxopropyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463304-73-6 CAPLUS
CN 1,3-Propanediol, 1-(2-naphthalenyl)-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463304-74-7 CAPLUS
CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(2-naphthalenyl)-1-oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 463304-62-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
RN 463304-62-3 CAPLUS
CN 1,3-Propanediol, 1-(1H-imidazol-4-yl)-1-(2-naphthalenyl)-, (1S)- (9CI)

L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:391718 CAPLUS
DOCUMENT NUMBER: 136:386117
TITLE: Preparation of 7-aryldihydropyrrolo[1,2-c]imidazol-7-ols and analogs as steroid 17-20-lyase inhibitors
INVENTOR(S): Tasaka, Akihiro; Hitaka, Takenori; Matsunaga, Nobuyuki; Kusaka, Masami; Adachi, Mari; Aoki, Isao; Ojida, Akio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040484	A2	20020523	WO 2001-JP10002	20011116
WO 2002040484	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014296	A5	20020527	AU 2002-14296	20011116
PRIORITY APPLN. INFO.:				
			JP 2000-351780	A 20001117
			JP 2001-247618	A 20010817
			JP 2001-336880	A 20011101
			WO 2001-JP10002	W 20011116


OTHER SOURCE(S): MARPAT 136:386117
GI




AB Title compds. {I; R = (un)substituted aryl; Z = (CH₂)₁₋₃} were prepd. Thus, 1-trityl-1H-imidazole-4-carboxaldehyde was condensed with MeCO₂Et in the presence of BuLi and the product converted in 2 steps to HOCH(R)CH₂CHO (R = 1-trityl-1H-imidazole-4-yl) which was cyclized to give 5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one. The latter was arylated by 5-methoxybenzo[b]thiophene to give I [R = 5-methoxybenzo[b]thiophen-2-yl, Z = CH₂]. Data for biol. activity of I were given.

IT 426219-47-8P 426219-55-8P 426219-56-9P
426219-58-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(prepn. of 7-aryldihydropyrrolo[1,2-c]imidazol-7-ols and analogs as steroid 17-20-lyase inhibitors)
RN 426219-47-8 CAPLUS
CN 2-Naphthalenecarboxamide, N,N-bis(1-methylethyl)-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 426219-55-8 CAPLUS
CN 1H-Imidazole-4-propanoic acid, .beta.-[6-[[bis(1-methylethyl)amino]carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 426219-56-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1,3-dihydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 426219-58-1 CAPLUS
CN 1H-Imidazole-4-propanoic acid, .beta.-[6-[[bis(1-methylethyl)amino]carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:391704 CAPLUS
 DOCUMENT NUMBER: 136:401756
 TITLE: Preparation of imidazole derivatives for treatment of prostate and breast cancer
 INVENTOR(S): Tasaka, Akihiro; Matsunaga, Nobuyuki; Ojida, Akio; Kusaka, Masami
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040470	A1	20020523	WO 2001-JP10079	20011119
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014320	A5	20020527	AU 2002-14320	20011119
JP 2002241377	A2	20020828	JP 2001-353524	20011119
PRIORITY APPLN. INFO.:				
			JP 2000-353634	A 20001120
			JP 2000-382056	A 20001215
			WO 2001-JP10079	W 20011119
OTHER SOURCE(S): MARPAT 136:401756				
GI				




AB The title compds., e.g. I [R is hydrogen or a protecting group; R1 is lower alkyl or cycloalkyl; and ring A is an optionally substituted 5- or 6-membered ring having an amide linkage], are prepd. I are steroid C17-20 lyase inhibitors and are useful in the treatment of prostate and breast cancer. The process for prepg. I is disclosed. 7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benz[e]isoindol-3-one inhibited the biosynthesis of testosterone in rats. Formulations are given.

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 IT 430472-50-7P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazole derivs. for treatment of prostate and breast cancer)
 RN 430472-50-7 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 430472-30-3P 430472-32-5P 430472-34-7P
 430472-36-9P 430472-38-1P 430472-39-2P
 430472-40-5P 430472-41-6P 430472-42-7P
 430472-43-8P 430472-44-9P 430472-45-0P
 430472-46-1P 430472-47-2P 430472-48-3P
 430472-49-4P 430472-51-8P 430472-52-9P
 430472-53-0P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazole derivs. for treatment of prostate and breast cancer)
 RN 430472-30-3 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-32-5 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-34-7 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-ethyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-36-9 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-(dimethylamino)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-38-1 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-(1-methylethyl)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-39-2 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-cyclopropyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-40-5 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-(2,2,2-trifluoroethyl)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-41-6 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-(2,2,2-trifluoroethyl)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-42-7 CAPLUS
 CN Benzo[f]phthalazin-4(1H)-one, 2,3-dihydro-8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-43-8 CAPLUS
 CN Benzo[f]phthalazin-4(1H)-one, 8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-44-9 CAPLUS
CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-45-0 CAPLUS
CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-46-1 CAPLUS
CN Benzo[g]phthalazin-1(2H)-one, 3,4-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-47-2 CAPLUS
CN Benzo[g]phthalazin-1(2H)-one, 7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 430472-52-9 CAPLUS
CN 1H-Imidazole-1-carboxylic acid, 4-[1-(2,3-dihydro-2-methyl-3-oxo-1H-benz[e]isoindol-7-yl)-1-hydroxy-2-methylpropyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 430472-53-0 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 247173-85-9 247174-16-9 337520-93-1
337521-09-2 337521-12-7 337521-14-9
337521-16-1 337521-18-3 337521-22-9
337521-24-1 337521-26-3 337521-83-2
430472-54-1 430472-55-2 430472-56-3
430472-57-4 430472-58-5 430472-59-6
430472-60-9 430472-61-0 430472-62-1
430472-63-2 430472-64-3 430472-69-8
430472-70-1 430472-71-2 430472-73-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of imidazole derivs. for treatment of prostate and breast cancer)
RN 247173-85-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 430472-48-3 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-49-4 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-51-8 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-, (-) (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-16-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337520-93-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-09-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-12-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-14-9 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-16-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-18-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methyl-2-naphthalenyl)-


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-55-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 3-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 430472-56-3 CAPLUS
CN Methanone, [6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 430472-57-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 430472-58-5 CAPLUS
CN Methanone, (6-hydroxy-5-methyl-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-24-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-26-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-83-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-54-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-59-6 CAPLUS
CN Methanesulfonic acid, trifluoro-, 1-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 430472-60-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-61-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-62-1 CAPLUS
CN 3H-Benz[e]isoxindol-3-one, 1,2-dihydro-2-methyl-7-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-63-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-64-3 CAPLUS
CN 2-Naphthalenecarboxamide, 1-formyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-69-8 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 430472-70-1 CAPLUS


L4 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:353314 CAPLUS
DOCUMENT NUMBER: 136:365878
TITLE: Methods and compositions for treatment of ocular neovascularization and neural injury
INVENTOR(S): Burke, James A.; Lin, Ton; Wheeler, Larry A.; De Vries, Gerald W.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036162	A2	20020510	WO 2001-US46014	20011101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030567	A5	20020515	AU 2002-30567	20011101
US 2002094998	A1	20020718	US 2001-998718	20011101
PRIORITY APPLN. INFO.: US 2000-244850P P 20001101 WO 2001-US46014 W 20011101				
AB Methods and compns. for the treatment of ocular neovascularization (CNV) and macular degeneration are disclosed. The invention includes combining laser treatment with administration of a neuroprotectant. Seven pigmented rabbits were dosed with either 0.5 mL 0.2% brimonidine or saline administered in 1 eye of each rabbit. One hour later, the animals were treated with a 10-min i.v. infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 min later in the lower fundus with a 689-nm diode laser at 50 J/cm ² , 600 mW/cm ² and a spot size of 1.5 mm. Brimonidine reduced the increase in retinal thickness (subretinal cyst + retina) in the lesion produced by PDT.				
IT 226571-05-7, AGN 795 423773-40-4, AGN 960				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(methods and compns. for treatment of ocular neovascularization and neural injury)				
RN 226571-05-7 CAPLUS				
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)				




RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 430472-71-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-[(methylamino)methyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-73-4 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:848687 CAPLUS
 DOCUMENT NUMBER: 136:146981
 TITLE: Investigations on inhibitors of human 17.alpha.-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17.alpha.-hydroxylase-17,20-lyase, part II
 AUTHOR(S): Schappach, A.; Holtje, H.-D.
 CORPORATE SOURCE: Department of Pharmacy, Institute of Pharmaceutical Chemistry, Heinrich Heine-University, Dusseldorf, Germany
 SOURCE: Pharmazie (2001), 56(11), 835-842
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB New methods in treatment of hormone-dependent diseases like prostate or breast cancer have become a major subject in medical and pharmaceutical research. Because of the direct correlation of cancer growth and hormone concn., inhibition of hormone biosynthesis presents a promising strategy in cancer therapy. The key enzyme in androgen biosynthesis is the 17.alpha.-hydroxylase-17,20-lyase a cytochrome P 450 system, which specifically converts gestagens to androgens. Because the 3D-structure of the enzyme is still unknown most recently a ligand-based design was used to gain deeper insights into protein structure and function. In this paper we present mol. modeling studies on compds. acting as competitive inhibitors of the human 17.alpha.-hydroxylase-17,20-lyase. The compds. developed by Hartmann et al. belong to two different structural classes and show a wide range of inhibitory potency. The physico-chem. properties of the mols. were investigated and compared by studying structural flexibility and by calcg. mol. interactions fields. The superimposition of all inhibitors in a low energy conformation yielded in the common pharmacophore. In the second part of the paper individual inhibitors were docked into the active site of the enzyme model of CYP17 developed in our group. The dynamic behavior and stability of the protein-inhibitor-complexes was studied. The protein ligand interactions obsd. in course of the mol. dynamics simulations correspond well with the exptl. data.
 IT 157058-47-4
 RL: PRP (Properties)
 (mol. modeling of human 17.alpha.-hydroxylase-17,20-lyase with steroidal and non-steroidal inhibitors)
 RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 isomer. The optically active isomer produced has a steroid C17,20 lyase inhibitory activity and is useful as a preventive/remedy for tumors such as prostatism and mammary cancer. Also provided is a novel optical resolver II or III. Thus, 1.0 g (RS)-1-(6,7-dimethoxynaphthalen-2-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (IV) (prepn. given) and 822 mg (-)-8-hydroxy-7,9-dioxo-6-phenyl-8-phosphaspiro[4.5]decan-8-one (V) were dissolved in 21 mL ethanol with heating, stirred at room temp. for 6 h, and filtered to give 670 mg (-)-IV.V salt (99% de) in 74% yield which (665 mg) was added to 150 mg 25% aq. NH₃, 30 mL H₂O, and 20 mL AcOEt, and stirred at room temp. for 30 min. The org. layer was sepd. and concd. in vacuo to give 368 mg (-)-IV (99% de) in 74% yield.
 IT 336102-55-7 336102-62-6P
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)
 RN 336102-55-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 336102-62-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-) (9CI) (CA INDEX NAME)

Rotation (-).



IT 247174-39-6 336102-65-9 336102-70-6
 336102-73-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)
 RN 247174-39-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-[(diphenylmethylene)amino]-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:319877 CAPLUS
 DOCUMENT NUMBER: 134:340525
 TITLE: Process for producing optically active naphthalene derivative and optical resolver therefor
 INVENTOR(S): Aoki, Isao; Adachi, Mari; Kawada, Mitsuru; Yamano, Toru; Taya, Naohiro
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030763	A1	20010503	WO 2000-JP7282	20001019
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LX, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000079499	A5	20010508	AU 2000-79499	20001019
EP 1227085	A1	20020731	EP 2000-969902	20001019
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2001187785	A2	20010710	JP 2000-320499	20001020
PRIORITY APPLN. INFO.:			JP 1999-301570	A 19991022
			JP 1999-301576	A 19991022
			WO 2000-JP7282	W 20001019
OTHER SOURCE(S):			MARPAT 134:340525	
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for producing an optically active isomer of a compd. represented by formula (I) which comprises: reacting a mixt. of naphthalene derivs. represented by formula I (wherein R represents a nitrogenous heterocyclic group; R1 represents hydrogen, a hydrocarbon group, or a mononuclear arom. heterocyclic group; R2 represents hydrogen or lower alkyl; symbol indicates the position of an asym. carbon atom; and R3 to R8 each represents hydrogen, a hydrocarbon group, hydroxy, etc., provided that R7 may be bonded to R6 or R8 to form a ring contg. an oxygen atom) with an optically active isomer of a 2-hydroxy-4-phenyl-1,3,2-dioxaphosphorinan-2-one or arom. ring-fused 2-hydroxy-1,3,2-dioxaphosphhepan-2-one compd. represented by formula (II) or (III), resp. (wherein ring A represents a benzene ring; R10 and R11 each represents hydrogen, a hydrocarbon group, etc. or R10 and R11 in combination represent alkylene; symbol indicates the position of an asym. carbon atom; and rings B and C each represents an arom. ring) to yield salts; sepg. the salts; and then isolating the target


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 336102-65-9 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336102-70-6 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 336102-73-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 247173-05-3P 247173-20-2P 247173-40-6P
 247173-41-7P 247173-54-2P 247173-70-2P
 247173-71-3P 247173-72-4P 247174-10-3P
 247174-11-4P 247174-12-5P 247174-40-9P
 247174-41-0P 247174-69-2P 336102-57-9P
 336102-59-1P 336102-61-5P 336102-63-7P
 336102-64-8P 336102-66-0P 336102-67-1P
 336102-69-3P 336102-71-7P 336102-72-8P
 336102-74-0P 336102-75-1P 336102-76-2P


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 337534-07-3P 337534-08-4P 337534-10-8P
 337534-11-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinane resolving agents)
 RN 247173-05-3 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-
 (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-
 methylethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-11-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS
 CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA
 INDEX NAME)




RN 247174-40-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-
 yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-70-2 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-
 (triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-71-3 CAPLUS
 CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-
 yl]- (9CI) (CA INDEX NAME)




RN 247173-72-4 CAPLUS
 CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX
 NAME)



RN 247174-10-3 CAPLUS
 CN Methanone, (6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]-
 (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247174-69-2 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-
 (triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 336102-57-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (.alpha.S)-, compd. with (-)-8-hydroxy-6-phenyl-7,9-dioxo-8-
 phosphaspiro[4.5]decane 8-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-56-8
 CMF C13 H17 O4 P


Rotation (-).



CM 2

CRN 336102-55-7
 CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




RN 336102-59-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-
 methylethyl)-, (-)-, compd. with (4S)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-
 dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-58-0
 CMF C19 H22 N2 O2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
Rotation (-).



CH 2
CRN 98674-91-0
CMF C11 H13 C12 O4 P


Absolute stereochemistry. Rotation (-).



RN 336102-61-5 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1
CRN 336102-60-4
CMF C19 H21 N3 O2

Rotation (+).




CH 2
CRN 98674-82-9
CMF C12 H17 O5 P

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylene-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1
CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).




CH 2
CRN 98674-83-0
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (-).



RN 336102-66-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1
CRN 336102-65-9
CMF C20 H22 N2 O3



CH 2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).



RN 336102-63-7 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (-)-4-(4-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1
CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).



CH 2
CRN 98674-89-6
CMF C11 H14 Cl O4 P

Rotation (-).




RN 336102-64-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-67-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1
CRN 336102-65-9
CMF C20 H22 N2 O3



CH 2
CRN 98674-90-9
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-69-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester, compd. with (4S)-4-(2-chlorophenyl)-2-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-68-2
CMF C19 H20 N2 O3



CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (-).




RN 336102-71-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-70-6
CMF C20 H23 N3 O2




L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 336102-74-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-73-9
CMF C18 H19 N3 O2



CM 2

CRN 98674-90-9
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-75-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-73-9
CMF C18 H19 N3 O2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-72-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (-)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-70-6
CMF C20 H23 N3 O2




CM 2

CRN 98674-91-0
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-76-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9
CMF C18 H19 N3 O2




CM 2

CRN 98674-82-9
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337534-07-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (11bR)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-55-7
 CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 39648-67-4
 CMF C20 H13 O4 P




RN 337534-08-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 98674-86-3
 CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-11-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
 CMF C18 H20 N2 O2


Rotation (-).



CM 2

CRN 98674-86-3
 CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




IT 336103-01-6P 336103-02-7P 336103-04-9P

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
 CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-80-7
 CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-10-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 337534-09-5
 CMF C18 H20 N2 O2

Rotation (-).



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

336103-06-1P 337534-12-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinanone resolving agents)

RN 336103-01-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-(aminocarbonyl)-, (1S,2R)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336103-00-5
 CMF C8 H13 N O3

Absolute stereochemistry.



CM 2


CRN 247173-41-7
 CMF C19 H22 N2 O3



RN 336103-02-7 CAPLUS
 CN Benzeneacetic acid, .alpha.-hydroxy-, (.alpha.S)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-41-7
 CMF C19 H22 N2 O3




CM 2

CRN 17199-29-0

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).




RN 336103-04-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-phenylpropyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
CMF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).




RN 336103-06-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-phenylpropyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CM 2

CRN 50573-41-6
CMF C8 H11 N O3 S

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CM 1

CRN 336103-05-0
CMF C20 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 337534-12-0 CAPLUS
CN Sulfamic acid, [(1S)-1-phenylethyl]-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)



CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:319876 CAPLUS
DOCUMENT NUMBER: 134:340505
TITLE: Preparation of imidazol-4-ylmethanols as steroid C17-20 lyase inhibitors
INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 166 pp.
CODEN: FIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030762	A1	20010503	WO 2000-JP7283	20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1222174	A1	20020717	EP 2000-969903	20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002080458	A2	20020319	JP 2000-327022	20001020
PRIORITY APPLN. INFO.: JP 1999-301556 A 19991022 JP 2000-189728 A 20000620 WO 2000-JP7283 W 20001019				
OTHER SOURCE(S): MARPAT 134:340505				
GI				




AB Title compds. (I) [wherein R = H or a protecting group; R1 = (cyclo)alkyl;

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 R3 and R5 = H, acyl, halo, or (un)substituted alkyl, hydroxyl, thio, or amino; R4 = (un)substituted aryl, heterocyclic, or carbamoyl; or R3 and R4 form a 5- or 6-membered O-contg. ring; or R4 and R5 form a 5- or 6-membered O-contg. ring; R6 = (halo)alkyl; n = 0-3; or salt thereof], which have an inhibitory activity on steroid C17-20 lyase, were prepd. For example, Me 6-(1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-2-naphthoate (prepn. given) was deesterified using NaOH and MeOH in THF, converted to the amide using MeNH₂, and deprotected using pyridinium chloride to give the imidazolyl naphthalenemethanol 11. 11 inhibited steroid C17-20 lyase with IC₅₀ of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving test compds. to control groups) of 4.5%. 1 are useful for the prevention and treatment of breast cancer or prostate cancer (no data).
 IT 247173-41-7P, 1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 247173-54-2P, N-[6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl]acetamide
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
 RN 247173-41-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT 247173-85-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol 247174-16-9P, 1-(6-tert-Butyldimethylsilyloxy-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 247174-38-5P, 1-(6-Bromonaphthalen-2-yl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 247174-39-6P, 1-[6-[(Diphenylmethylene)amino]naphthalen-2-yl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 247174-41-0P, N-[6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]naphthalen-2-yl]acetamide 336103-03-0P, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337520-93-1P 337520-95-3P 337520-97-5P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile 337520-99-7P 337521-03-6P,


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol 337521-05-8P 337521-07-0P, Methyl 1-chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337521-09-2P 337521-12-7P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthol 337521-14-9P 337521-16-1P, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthoate 337521-18-3P, 1-(6-tert-Butyldimethylsilyloxy-7-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-22-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthol 337521-24-1P 337521-26-3P 337521-28-5P, (6-tert-Butyldimethylsilyloxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanol 337521-31-0P, (6-tert-Butyldimethylsilyloxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanone 337521-33-2P, (6-Hydroxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanone 337521-35-4P 337521-37-6P, Methyl 6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthoate 337521-39-8P, N-Methyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 337521-47-8P 337521-51-4P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthol 337521-53-6P 337521-55-8P, Methyl 6-[1-hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthoate 337521-57-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl-1-naphthamide 337521-58-1P 337521-60-5P, 2-Hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide 337521-61-6P, 2-Hydroxy-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-62-7P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide 337521-63-8P 337521-64-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-67-2P, 2-Methyl-1-(6-phenyl-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-69-4P, 1-[6-(2-Furyl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-72-9P, 2-Methyl-1-[6-(2-thienyl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-75-2P 337521-76-3P, 2-Methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-78-5P, 2-Methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-80-9P 337521-82-1P, 2-Methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-83-2P, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337521-85-4P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-88-7P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methoxy-2-naphthamide 337521-92-3P, (Naphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)methanol 337521-93-4P, (Naphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)ketone 337521-94-5P, (1H-Imidazol-4-yl) (naphtho[2,1-b]furan-7-yl)ketone 337521-99-0P, (1H-Imidazol-4-yl) [naphtho[2,3-d] [1,3]dioxol-6-yl]ketone 337522-06-2P, (2,3-Dihydro-1H-benzo[f]chromen-8-yl) (1-trityl-1H-imidazol-4-yl)methanol 337522-07-3P, (2,3-Dihydro-1H-benzo[f]chromen-8-yl) (1-trityl-1H-imidazol-4-yl)ketone 337522-08-4P, (2,3-Dihydro-1H-benzo[f]chromen-8-yl) (1H-imidazol-4-yl)ketone 337522-16-4P, (1,2-Dihydronaphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)methanol 337522-18-6P, (1,2-Dihydronaphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)ketone

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 337522-19-7P, (1,2-Dihydronaphtho[2,1-b]furan-7-yl) (1H-imidazol-4-yl)ketone 337522-26-6P, (2,3-Dihydronaphtho[2,3-b]furan-6-yl) (1H-imidazol-4-yl)methanol 337522-27-7P, (2,3-Dihydronaphtho[2,3-b]furan-6-yl) (1H-imidazol-4-yl)ketone 337522-28-8P, 1-(2,3-Dihydronaphtho[2,3-b]furan-6-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-29-9P, 1-(1-Benzyloxymethyl-1H-imidazol-4-yl)-1-(6,7-dimethoxy-2-naphthyl)-2-methyl-1-propanol 337522-43-7P, N-Ethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-47-1P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-propyl-2-naphthamide 337522-51-7P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-isopropyl-2-naphthamide 337522-55-1P, N-Butyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-59-5P, N-Cyclopropyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-63-1P, N-Cyclobutyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-66-4P, N-Cyclopropylmethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-68-6P, N-Cyclopentyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-70-0P, N-Cyclohexyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-73-3P, N-Cycloheptyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-75-5P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-78-0P, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-81-3P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthamide 337522-85-7P, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337522-91-5P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,1-dimethyl-2-naphthamide 337522-96-0P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,3-dimethyl-2-naphthamide 337523-01-0P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthamide 337523-04-3P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,N-dimethyl-2-naphthamide 337523-08-7P, 2-Methyl-1-[6-(1-pyrrolidinylcarbonyl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337523-14-5P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(1,3-thiazol-2-yl)-2-naphthamide 337523-18-9P, N-Ethoxy-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337523-22-5P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-isopropoxy-2-naphthamide 337523-25-8P, N-(2-Hydroxyethyl)-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337523-29-2P, Ethyl [[6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoyl]amino]acetate 337523-34-9P 337523-37-2P 337523-41-8P, 6-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-43-0P, 6-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)-2-propenyl]-N-methyl-2-naphthamide 337523-45-2P, 6-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337523-49-6P 337523-53-2P, 6-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)-3-butenyl]-N-methyl-2-naphthamide 337523-55-4P, 6-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-59-8P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-69-0P, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthonitrile 337523-71-4P, 1-[5-Chloro-6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337523-73-6P, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 337523-78-1P, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthaldehyde 337523-80-5P, 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337523-84-9P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthamide 337523-88-3P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthonitrile 337523-90-7P, 3-Methyl-1-[6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337523-92-9P, 3-Methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337523-96-3P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthaldehyde 337523-98-5P, 3-Methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337524-02-4P, 1-[6-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337524-08-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
 RN 247173-85-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-16-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-38-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-39-6 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-[6-[(diphenylmethylene)amino]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-41-0 CAPLUS


CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 336103-03-8 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 337520-93-1 CAPLUS


CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-05-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-07-0 CAPLUS

CN 2-Naphthalenecarboxylic acid, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 337521-09-2 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-12-7 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337520-95-3 CAPLUS

CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337520-97-5 CAPLUS

CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337520-99-7 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-03-6 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-14-9 CAPLUS

CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-16-1 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 337521-18-3 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-24-1 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-26-3 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-28-5 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-31-0 CAPLUS
 CN Methanone, [6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-47-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-51-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-hydroxy-2-naphthalenyl]-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-53-6 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-55-8 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-33-2 CAPLUS
 CN Methanone, (6-hydroxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337521-35-4 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-37-6 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-39-8 CAPLUS
 CN 2-Naphthalenecarboxamide, N-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-57-0 CAPLUS
 CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-58-1 CAPLUS
 CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-60-5 CAPLUS
 CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-61-6 CAPLUS
 CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-2-methyl-1-[1-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-62-7 CAPLUS
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-63-8 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-[(methylamino)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-64-9 CAPLUS
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-76-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-78-5 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-tetrazol-5-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-80-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-1-(triphenylmethyl)-.alpha.-[6-(1-(triphenylmethyl)-1H-pyrazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-82-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-67-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(phenyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-69-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-furanyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-72-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-thienyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-75-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-83-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 337521-85-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-88-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-92-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-93-4 CAPLUS
CN Methanone, naphtho[2,1-b]furan-7-yl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337521-94-5 CAPLUS
CN Methanone, 1H-imidazol-4-yl-naphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)




RN 337521-99-0 CAPLUS
CN Methanone, 1H-imidazol-4-yl-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)




RN 337522-06-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-19-7 CAPLUS
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-26-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)- (9CI) (CA INDEX NAME)




RN 337522-27-7 CAPLUS
CN Methanone, (2,3-dihydronaphtho[2,3-b]furan-6-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-28-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-07-3 CAPLUS
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337522-08-4 CAPLUS
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-16-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337522-18-6 CAPLUS
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-29-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 337522-43-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337522-47-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-51-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-55-1 CAPLUS
CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-59-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 337522-63-1 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337522-66-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337522-68-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-81-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 337522-85-7 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337522-91-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337522-96-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-70-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 337522-73-3 CAPLUS
CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337522-75-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337522-78-8 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-01-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 337523-04-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-08-7 CAPLUS
CN Pyrrolidine, 1-[[6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 337523-14-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-18-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337523-22-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-25-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337523-29-2 CAPLUS
CN Glycine, N-[[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337523-43-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-propenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-45-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-49-6 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[cyclopropylhydroxy[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-53-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-3-butenyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-34-9 CAPLUS
CN L-Alanine, N-[[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-37-2 CAPLUS
CN D-Alanine, N-[[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-41-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337523-55-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-59-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-69-0 CAPLUS
CN 2-Naphthalenecarbonitrile, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337523-71-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-73-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-78-1 CAPLUS
 CN 2-Naphthalenecarboxaldehyde, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337523-80-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-(5-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-84-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-88-3 CAPLUS

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337524-02-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337534-08-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
 CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




CM 2


CRN 98674-80-7
 CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-90-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337523-92-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-96-3 CAPLUS
 CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-98-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-[5-(5-oxazolyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 337521-96-7P, 1-(1H-Imidazol-4-yl)-1-(naphtho[2,3-d][1,3]dioxol-6-yl)-2-methyl-1-propanol 337522-45-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide 337522-94-8P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide 337523-27-0P, Ethyl [[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoyl]amino]acetate 337523-39-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-51-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-67-8P, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 337521-96-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(naphtho[2,3-d]-1,3-dioxol-6-yl)- (9CI) (CA INDEX NAME)




RN 337522-45-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-94-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-27-0 CAPLUS

CN Glycine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 337523-39-4 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-51-0 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-67-8 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


methylpropyl]-2-naphthamide 337522-79-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl-2-naphthamide 337522-83-5P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337522-88-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl-2-naphthamide 337522-99-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl-2-naphthamide 337523-03-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl-2-naphthamide 337523-06-5P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1-pyrrolidinylcarbonyl)-2-naphthyl]-1-propanol 337523-11-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1,3-thiazol-2-yl)-2-naphthamide 337523-16-7P, N-Ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-20-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropoxy-2-naphthamide 337523-24-7P, N-(2-Hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-32-7P 337523-36-1P 337523-47-4P 337523-61-2P, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337523-63-4P, (S)-(-)-N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-65-6P, (S)-(-)-N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-76-9P, 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337523-82-7P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-naphthamide 337523-86-1P, 1-(1H-Imidazol-4-yl)-3-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-butanol 337523-94-1P, 1-(1H-Imidazol-4-yl)-3-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-butanol 337524-00-2P, 1-[6-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337524-05-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 336102-55-7 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 336102-68-2 CAPLUS


CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 336102-55-7P, (S)-(-)-1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 336102-68-2P, Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate 336102-70-6P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-2-naphthamide 336102-73-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-66-1P, 1-(1H-Imidazol-4-yl)-2-methyl-1-(6-phenyl-2-naphthyl)-1-propanol 337521-68-3P, 1-[6-(2-Furyl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337521-70-7P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(2-thienyl)-2-naphthyl]-1-propanol 337521-74-1P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-propanol 337521-77-4P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-propanol 337521-79-6P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-pyrazol-4-yl)-2-naphthyl]-1-propanol 337521-81-0P, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-propanol 337521-84-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337521-86-5P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy-2-naphthamide 337521-89-8P, 1-(1H-Imidazol-4-yl)-1-(naphtho[2,1-b]furan-7-yl)-2-methyl-1-propanol 337521-95-6P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-00-6P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-09-5P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)ethanol 337522-10-8P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)propanol 337522-12-0P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-ethanol 337522-21-1P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-propanol 337522-31-3P 337522-33-5P, (-)-N-[6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl]acetamide 337522-40-4P 337522-41-5P, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-49-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-2-naphthamide 337522-53-9P, N-Butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-57-3P, N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-61-9P, N-Cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-64-2P, N-Cyclopropylmethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-67-5P, N-Cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-69-7P, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-72-2P, N-Cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-74-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-77-7P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 336102-70-6 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 336102-73-9 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-66-1 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-phenyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-68-3 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-(2-furanyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-70-7 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-thienyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-74-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-77-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-tetrazol-5-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-79-6 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-pyrazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-95-6 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-00-6 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-09-5 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-10-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-81-0 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-84-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-86-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-89-8 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 337522-12-0 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 337522-21-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)




RN 337522-31-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7

CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 337522-33-5 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 337522-40-4 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 337522-33-5
CMF C19 H21 N3 O2

Rotation (-).




CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-61-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-64-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-67-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-69-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-41-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-49-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-53-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-57-3 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-72-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-74-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-77-7 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-79-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 337522-83-5 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-88-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl)- (9CI) (CA INDEX NAME)



RN 337522-99-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl)- (9CI) (CA INDEX NAME)




RN 337523-03-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl)- (9CI) (CA INDEX NAME)




RN 337523-06-5 CAPLUS
CN Pyrrolidine, 1-([6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-32-7 CAPLUS
CN L-Alanine, N-([6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-36-1 CAPLUS
CN D-Alanine, N-([6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-47-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-(cyclopropylhydroxy-1H-imidazol-4-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-61-2 CAPLUS


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-11-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 337523-16-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethoxy-6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337523-20-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-24-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-([1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 2-Naphthalenecarboxamide, 6-([1S]-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-63-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-([1S]-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-([1S]-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-76-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-(5-oxazolyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-82-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]- (9CI) (CA INDEX NAME)



RN 337523-86-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337523-94-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337524-00-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-97-1 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337524-05-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
 CHF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
 CHF C4 H4 O4

Double bond geometry as shown.



IT 247174-44-3, 6-[1-Hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthaldehyde 337522-97-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
 RN 247174-44-3 CAPLUS
 CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:85068 CAPLUS
 DOCUMENT NUMBER: 134:260881
 TITLE: Potential Antidepressants Displayed Combined .alpha.2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties
 AUTHOR(S): Cordi, Alex A.; Berque-Bestel, Isabelle; Persigand, Thierry; Lacoste, Jean-Michel; Newman-Tancredi, Adrian; Audinot, Valerie; Millan, Mark J.
 CORPORATE SOURCE: Institut de Recherches Servier, Suresnes, F-92150, Fr.
 SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 787-805
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metab. (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3-6 wk) before robust clin. efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic .alpha.2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic .alpha.2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two mols. have been described with such a pharmacol. profile. Of these, napamezole was chosen as a point of departure for the design of 4(5)-[3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole, which displayed the desired profile: .alpha.2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original mol., a series of derivs. was designed and synthesized, encompassing substituted as well as rigid analogs. Structure-activity relationships permitted the selection of 4(5)-[5-fluoroindan-2-yl)methyl]-4,5-dihydroimidazole as a development candidate.


IT 331992-77-9P 331992-78-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and structure-activity relations of potential antidepressants displaying combined .alpha.2-adrenoceptor antagonist and monoamine uptake inhibitor activities)

RN 331992-77-9 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 331992-78-0 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12424 CAPLUS
 DOCUMENT NUMBER: 134:86245
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors.
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000586	A1	20010104	WO 2000-US15795	20000608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1104407	A1	20010606	EP 2000-939699	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPLN. INFO.: US 1999-329752 A 19990610 US 1997-985347 B2 19971204 US 1998-205597 B2 19981204 WO 2000-US15795 W 20000608 US 2000-679919 A1 20001005				
OTHER SOURCE(S): MARPAT 134:86245 GI				



AB Title compds. [I: dotted lines = optional double bonds; R = H, alkyl; X = S, CHR1; R1 = H, alkyl, null; Y = O, N, S, [C(R1)n]y, CH:CH, Y1CH2; y = 1-3; n = 1, 2; R2 = H, alkyl, halo, OH, alkoxy, alkenyl, acyl, alkynyl, etc.; R3, R4 = H, alkyl, halo, alkenyl, acyl, alkynyl, etc.; R3R4 = atoms to form (unsatd.) (heterocyclic) ring], were prep'd. Thus, 1-(dimethylsulfamoyl)imidazole in THF at -78.degree. was treated with BuLi and tert-butyldimethylsilyl chloride followed by warming to room temp., stirring overnight, cooled to -20.degree., and treatment with BuLi and

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

3-thiophenecarboxaldehyde followed by warming to room temp. and stirring overnight to give 2-(tert-butyldimethylsilyl)-5-(hydroxythiophen-2-ylmethyl)imidazole-1-sulfonic acid dimethylamide. This was treated sequentially with Bu4NF, Et3SiH/CF3CO2H/CH2Cl2, and aq. HCl to give 4(5)-thiophen-3-ylmethyl-1H-imidazole. Tested I as eyedrops at 0.03-1% reduced intraocular pressure in cynomolgus monkeys by 12.4-33% and showed no sedative activity.


IT 157058-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT 157058-55-4P 226570-89-4P 226571-02-4P


226571-05-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)


RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 226571-02-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



IT 157058-44-1 157058-52-1 226571-13-7

226571-14-8 226571-25-1 226571-26-2


226571-35-3 226571-36-4 226571-37-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-14-8 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 226571-25-1 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI)
(CA INDEX NAME)




RN 226571-35-3 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI)
(CA INDEX NAME)

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-36-4 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI)
(CA INDEX NAME)



IT 226571-57-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI)
(CA INDEX NAME)







REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2000:911226 CAPLUS
DOCUMENT NUMBER: 134:56671
TITLE: Process for the preparation of 4-alkanoylimidazole derivatives and 1-(2-naphthyl)-1-(1H-imidazol-4-yl)alkanol derivatives
INVENTOR(S): Kawakami, Jun-ichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078727	A1	20001228	WO 2000-JP4036	20000621
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001064264	A2	20010313	JP 2000-191081	20000621
EP 1193258	A1	20020403	EP 2000-940770	20000621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:				JP 1999-175070 A 19990622
				WO 2000-JP4036 W 20000621
OTHER SOURCE(S): CASREACT 134:56671; MARPAT 134:56671				
GI				



AB An industrially advantageous process for the prepn. of compds. of general formula (I); wherein the ring A is an optionally substituted imidazole ring; R is an optionally substituted hydrocarbon group or a heterocyclic


L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 group; and R1, R2, R3, R4, R5, R6, and R7 are each hydrogen, optionally substituted hydrocarbyl, OH, SH, NH2, acyl, halogeno, or the like)
 comprises addn. reaction of 4-cyanoimidazole (II; the ring A is same as above) with R-M1 (R is same as above; M1 = alkali metal, Mg-Y1; Y1 = halo) to give 4-acylimidazole (III; R and ring A are same as above), followed by addn. reaction of III with naphthalene alkali metals (IV; R1 - R7 are = same as above; M2 is alkali metal, Mg-Y2; Y2 is halo). This process is reduced in the no. of steps, attains a high yield, and dispenses with the use of a heavy metal compd. The compds. I exhibit a steroid C17-C20 lyase inhibitory activity (no data). Thus, a soln. of 42.7 g 4-cyanoimidazole in 500 mL THF was added dropwise to a 1.1 M soln. of isopropylmagnesium bromide in THF (1.4 L) over a period of 30 min, stirred at 15-25.degree., treated dropwise with 10% aq. H2SO4, stirred for 30 min, neutralized to pH 8 with 30 aq. NaOH, and extd. with EtOAc (300 L .times. 2) to give 82% 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (V). 2-Bromo-6-methoxynaphthalene (5.15 g) was added dropwise to a mixt. of 0.55 g and 3 mg iodine in THF at 50.degree. and stirred at 15-25.degree. for 1.5 h, followed by adding dropwise a soln. of 1 g V in THF, and the resulting mixt. was stirred at 15-25.degree. for 8 h to give, after workup, 84% 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol.
 IT 247173-05-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 4-alkanoylimidazole derivs. and .alpha.-(2-naphthyl)-.alpha.-(1H-imidazolyl)alkanol derivs. by addn. reaction of cyanoimidazoles with alkylmagnesium bromides followed by naphthylmagnesium bromide)
 RN 247173-05-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:691084 CAPLUS
 DOCUMENT NUMBER: 131:299449
 TITLE: Preparation of azolymethylnaphthalenes and related compounds as steroid C17,20-lyase inhibitors.
 INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954309	A1	19991028	WO 1999-JP2143	19990422
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2328973	AA	19991028	CA 1999-2328973	19990422
JP 2000007658	A2	20000111	JP 1999-114398	19990422
EP 1073640	A1	20010207	EP 1999-917102	19990422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			JP 1998-113801	A 19980423
			WO 1999-JP2143	W 19990422
OTHER SOURCE(S): MARPAT 131:299449				
GI				




AB Title compds. {I; A1 = (substituted) imidazolyl, thiazolyl, oxazolyl, pyridyl; R11 = H, (substituted) hydrocarbyl, monocyclic heteroaryl; R21 = H, (substituted) alkyl; R3-R9 = H, (substituted) hydrocarbyl, OH, SH, amino, acyl, halo; R21 = (substituted) alkyl}, and salts or prodrugs thereof, were prepd. Thus, 2-bromo-6-methoxynaphthalene in THF at -78.degree. was treated with BuLi and then with 4-formyl-1-trityl-1H-imidazole to give (6-methoxynaphthalen-2-yl)(1-trityl-1H-imidazol-4-yl)methanol. The product was refluxed with MnO2 in CHCl3 to give the ketone, which was detritylated with HCO2H in THF to give (1H-imidazol-4-yl)(6-methoxynaphthalen-2-yl) ketone. The latter in THF at

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 -10.degree. was treated with Me2CHMgBr in THF to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methyl-1-propanol. This inhibited rat steroid C17,20-lyase with IC50 = 33 nM. I drug formulations are given.
 IT 247173-05-3P 247173-06-4P 247173-07-5P
 247173-09-7P 247173-11-1P 247173-12-2P
 247173-13-3P 247173-14-4P 247173-17-7P
 247173-18-8P 247173-19-9P 247173-20-2P
 247173-21-3P 247173-22-4P 247173-23-5P
 247173-24-6P 247173-25-7P 247173-26-8P
 247173-27-9P 247173-28-0P 247173-29-1P
 247173-30-4P 247173-31-5P 247173-32-6P
 247173-33-7P 247173-34-8P 247173-35-9P
 247173-36-0P 247173-37-1P 247173-38-2P
 247173-39-3P 247173-40-6P 247173-41-7P
 247173-42-8P 247173-43-9P 247173-44-0P
 247173-45-1P 247173-46-2P 247173-47-3P
 247173-48-4P 247173-49-5P 247173-50-8P
 247173-51-9P 247173-52-0P 247173-53-1P
 247173-54-2P 247173-55-3P 247173-56-4P
 247173-57-5P 247173-58-6P 247173-59-7P
 247173-60-0P 247173-61-1P 247173-62-2P
 247173-63-3P 247173-64-4P 247173-65-5P
 247173-66-6P 247173-68-8P 247173-69-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)
 RN 247173-05-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-06-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 247173-07-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-09-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 247173-08-6
 CMF C18 H18 N2 O2




CM 2
 CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 247173-11-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 247173-10-0
 CMF C19 H22 N2 O2




CM 2
 CRN 110-17-8
 CMF C4 H4 O4

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Double bond geometry as shown.




RN 247173-12-2 CAPLUS
CN 3-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-13-3 CAPLUS
CN 4-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-14-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 247173-17-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-fluoro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-22-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-23-5 CAPLUS
CN 1H-Imidazole-1,4-dimethanol, .alpha.4-(6-hydroxy-2-naphthalenyl)-.alpha.4-(1-methylethyl)-, .alpha.1-acetate (9CI) (CA INDEX NAME)



RN 247173-24-6 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 247173-25-7 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 247173-26-8 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-18-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)



RN 247173-19-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)




RN 247173-21-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-cyclopentyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 247173-27-9 CAPLUS
CN 1H-Imidazole, 4-[(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 247173-28-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 247173-29-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-30-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-{1-[[[1,1-dimethylethyl]dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 247173-31-5 CAPLUS
 CN 1,6-Naphthalenedimethanol, .alpha.-6-1H-imidazol-4-yl-2-methoxy-.alpha.1-methyl-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-32-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(phenylmethoxy)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-33-7 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5-(1-methylethenyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-34-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5-(1-methylethyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-35-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247173-36-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-(1-methylethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-37-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-38-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247173-39-3 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-(2-methoxyethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-42-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-43-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(5,6-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-44-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-hydroxy-7-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-45-1 CAPLUS
 CN 1,6-Naphthalenedimethanol, .alpha.6-1H-imidazol-4-yl-2-methoxy-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-46-2 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5-(methoxymethyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-47-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-48-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-49-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-bromo-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-50-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-(fluoromethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-55-3 CAPLUS
CN Urea, N'-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 247173-56-4 CAPLUS
CN Urea, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 247173-57-5 CAPLUS
CN Methanesulfonamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-58-6 CAPLUS
CN 2,6-Naphthalenedimethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-51-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-52-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-53-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247173-59-7 CAPLUS
CN Ethanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-60-0 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-61-1 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247173-62-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-63-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-64-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-65-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-66-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-68-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(6-propyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-71-3 CAPLUS
CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-73-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-74-6 CAPLUS
CN 3-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247173-69-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT 247174-67-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)


RN 247174-67-0 CAPLUS
CN Methanone, (5-fluoro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




IT 247173-70-2P 247173-71-3P 247173-72-4P
247173-73-5P 247173-74-6P 247173-75-7P
247173-76-8P 247173-81-5P 247173-82-6P
247173-83-7P 247173-85-9P 247173-86-0P
247173-88-2P 247173-89-3P 247173-90-6P
247173-92-8P 247173-93-9P 247173-94-0P
247173-95-1P 247173-98-4P 247173-99-5P
247174-00-1P 247174-01-2P 247174-03-4P
247174-04-5P 247174-05-6P 247174-06-7P
247174-07-8P 247174-08-9P 247174-09-0P
247174-10-3P 247174-11-4P 247174-12-5P
247174-16-9P 247174-17-0P 247174-24-9P
247174-25-0P 247174-26-1P 247174-29-4P
247174-31-8P 247174-35-2P 247174-36-3P
247174-38-5P 247174-39-6P 247174-40-9P
247174-41-0P 247174-42-1P 247174-43-2P
247174-44-3P 247174-45-4P 247174-46-5P
247174-47-6P 247174-48-7P 247174-50-1P
247174-51-2P 247174-52-3P 247174-54-5P
247174-63-6P 247174-64-7P 247174-65-8P
247174-66-9P 247174-69-2P 247174-72-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)

RN 247173-70-2 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-75-7 CAPLUS
CN 4-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-76-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-81-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(phenylmethoxy)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-82-6 CAPLUS
CN Methanone, [6-(phenylmethoxy)-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-83-7 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(phenylmethoxy)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-85-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-86-0 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-(acetyloxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-88-2 CAPLUS
CN 1H-imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-94-0 CAPLUS
CN 1H-imidazole, 4-[(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-95-1 CAPLUS
CN Methanone, (5-chloro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 247173-98-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(5-[1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl)-6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-99-5 CAPLUS
CN Methanone, [5-[1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-99-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 247173-90-6 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-92-8 CAPLUS
CN 1H-imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-93-9 CAPLUS
CN 1H-imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-00-1 CAPLUS
CN Methanone, [5-[1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-01-2 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-(phenylmethoxy)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247174-03-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5-(1-methylethenyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-04-5 CAPLUS
CN Methanone, [6-methoxy-5-(1-methylethenyl)-2-naphthalenyl][1-


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247174-05-6 CAPLUS
 CN Methanone, 1H-imidazol-4-yl[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-06-7 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247174-07-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-16-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-17-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247174-24-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-25-0 CAPLUS
 CN Methanone, 1H-imidazol-4-yl[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 247174-08-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247174-09-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-methoxyethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-10-3 CAPLUS
 CN Methanone, (6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247174-11-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS
 CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-26-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247174-29-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-31-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-(fluoromethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-35-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5,7-dimethyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-36-3 CAPLUS

CN Methanone, 1H-imidazol-4-yl(6-methoxy-5,7-dimethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247174-38-5 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-39-6 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-[6-[(diphenylmethylene)amino]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-40-9 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-46-5 CAPLUS

CN Ethanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-47-6 CAPLUS

CN 1-Propanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-48-7 CAPLUS

CN 1-Propanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247174-50-1 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-ethenyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-42-1 CAPLUS

CN Urea, N'-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 247174-43-2 CAPLUS

CN Methanesulfonamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-44-3 CAPLUS


CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 247174-45-4 CAPLUS


CN 2,6-Naphthalenedimethanol, .alpha.-(1-methylethyl)-.alpha.-(1-(triphenylmethyl)-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-51-2 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-52-3 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-54-5 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-63-6 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-propenyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-64-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-65-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethenyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-66-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-69-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-72-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propoxy-2-

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:375530 CAPLUS
DOCUMENT NUMBER: 131:19013
TITLE: Preparation of .alpha.2B and .alpha.2C adrenoceptor agonists
INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928300	A1	19990610	WO 1998-US25669	19981203
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, XG, XZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2312334	AA	19990610	CA 1998-2312334	19981203
AU 9918025	A1	19990616	AU 1999-18025	19981203
AU 744798	B2	20020307		
EP 1036065	A1	20000920	EP 1998-962883	19981203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
BR 9813381	A	20001003	BR 1998-13381	19981203
JP 2001524542	T2	20011204	JP 2000-523194	19981203
NO 2000002773	A	20000802	NO 2000-2773	20000530
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPLN. INFO.:			US 1997-985347	A 19971204
			WO 1998-US25669	W 19981203
			US 1998-205597	B2 19981204
			US 1999-329752	B3 19990610
			US 2000-679919	A1 20001005


OTHER SOURCE(S): MARPAT 131:19013

AB Title compds. of diverse structural type were prepd. Thus, 7-methoxy-1-tetralone was condensed with 1-dimethylsulfamoyl-2-tert-butylidimethylsilyl-5-imidazolecarboxaldehyde (prepn. given) and the product converted in 3 steps to 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1H-imidazole. Data for biol. activity of title compds. were given.


IT 157058-44-1P 157058-47-4P 157058-52-1P
157058-55-4P 226570-89-4P 226571-02-4P
226571-05-7P 226571-13-7P 226571-14-8P
226571-25-1P 226571-26-2P 226571-35-3P
226571-36-4P 226571-37-5P 226571-43-3P
226571-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)


RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
INDEX NAME)


RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 226571-02-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-
 (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]-
 (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl-
 (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]-
 (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-
 (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 226571-43-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-55-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-,
 (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 226571-05-7
 CMF C14 H20 N2



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



IT 226571-57-9p
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)
 RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-


L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:244636 CAPLUS
DOCUMENT NUMBER: 130:252360
TITLE: Preparation of dihydronaphthalene compounds
INVENTOR(S): Hartmann, Rolf Wolfgang; Wachall, Bertil; Yoshihama, Makoto; Nakakoshi, Masamichi; Nomoto, Shin; Ikeda, Yoshikazu
PATENT ASSIGNEE(S): Yukiijirushi Nyugyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918075	A1	19990415	WO 1998-JP4426	19981001
W: AU, CA, CN, FI, HU, IL, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9808954	A	19990412	ZA 1998-8954	19981001
AU 9892810	A1	19990427	AU 1998-92810	19981001
AU 743405	B2	20020124		
EP 1028110	A1	20000816	EP 1998-945556	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
FI 2000000207	A	20000201	FI 2000-207	20000201
NO 2000001289	A	20000310	NO 2000-1289	20000310
US 2002032211	A1	20020314	US 2001-866179	20010525
PRIORITY APPLN. INFO.:			JP 1997-284263	A 19971002
			WO 1998-JP4426	W 19981001
			US 1999-424126	B1 19991117
OTHER SOURCE(S):		MARPAT 130:252360		
GI				




AB Dihydronaphthalene compds. I (R1 = H, OH, alkyloxy; R2 = alkyl, aralkyl, Ph; R3 = alkyl, Ph, pyridyl, imidazolyl), useful as 17.alpha.-hydroxylase/C17-20-lyase inhibitors, thromboxane A2 synthesis inhibitors, and aromatase inhibitors, were prepd. I (R1 = H, R2 = Me, R3 = 3-pyridyl) showed 17.alpha.-hydroxylase/C17-20-lyase and aromatase inhibitor activity.
IT 157058-45-2P 157058-46-3P 157058-47-4P
221651-52-1P 221651-54-3P 221651-56-5P
221651-61-2P 221651-64-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of dihydronaphthalenes)


L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 221651-56-5 CAPLUS
CN 1(2H)-Naphthalenone, 7-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)



RN 221651-61-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-propoxy-(9CI) (CA INDEX NAME)




RN 221651-64-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-(2-methylpropoxy)-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy-(9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy-(9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)




RN 221651-52-1 CAPLUS
CN 1(2H)-Naphthalenone, 5-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)



RN 221651-54-3 CAPLUS
CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:543217 CAPLUS
DOCUMENT NUMBER: 129:149262
TITLE: Preparation and biological activity of imidazopyridoindole and imidazopyridobenzothiophene combinatorial libraries
INVENTOR(S): Ostresh, John M.
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834112	A1	19980806	WO 1997-US22286	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5856107	A	19990105	US 1997-794364	19970204
AU 9853740	A1	19980825	AU 1998-53740	19971205
PRIORITY APPLN. INFO.:			US 1997-794364	19970204
			WO 1997-US22286	19971205
OTHER SOURCE(S):		MARPAT 129:149262		
GI				




AB The invention provides a rapid approach for combinatorial synthesis and screening of libraries of imidazopyridoindole and imidazopyridobenzothiophenes I [R1 = H, halo, (un)protected OH, amino, (un)protected carboxy; R2 = H, (un)substituted C1-10 alkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted C3-7 cycloalkyl, (un)substituted naphthyl; R2 may form piperidine or benzopiperidine ring with the adjacent N; R3 = (un)substituted C1-10 alkyl, (un)substituted C2-10 alkenyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted naphthyl, (un)substituted heterocycle; X = N, S; Y = H, Me]. The present invention further provides methods of prepg. the libraries and the individual compds. made by the combinatorial synthesis. Reactivity ratios for amidation of 85 carboxylic acids to resin-bound dipeptide derivs. are also given, along with reactivity ratios for solid-phase peptide coupling of 25 N-protected amino acids. Thus, 121 sublibraries I, prepd. by

L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 systematically varying R1 (and X and Y), R2, and R3 were prepd. via solid-phase peptide coupling of a tryptophan or (benzothienyl)alanine deriv. (variables R1, X, and Y) to a benzhydrylamine resin, coupling of another amino acid residue (variable R2), coupling of a carboxylic acid residue (variable R3), POCl3-induced ring closure, and HF resin cleavage. All 121 prepd. sublibraries were tested for antimicrobial activity and .mu.-opioid receptor binding.
 IT 210982-44-8DP, combinatorial library derivs. 210983-86-1DP, combinatorial library derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and biol. activity of imidazopyridindole and imidazopyridobenzothiophene combinatorial libraries)
 RN 210982-44-8 CAPLUS
 CN 5H-Imidazo[1',5':1,2]pyrido[3,4-b]indole-5-carboxamide, 6,11-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 210983-86-1 CAPLUS
 CN [1]Benzothieno[2,3-c]imidazo[1,5-a]pyridine-5-carboxamide, 5,6-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (synthesis and evaluation ofazole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-52-1P 157058-53-2P 157058-55-4P 178880-06-3P

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:358249 CAPLUS
 DOCUMENT NUMBER: 125:75343
 TITLE: Synthesis and evaluation ofazole-substituted tetrahydronaphthalenes as inhibitors of P450 aom, P450 17 and P450 TxA2
 AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.
 CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261
 CODEN: ARPMAS; ISSN: 0365-6233
 PUBLISHER: VCH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 aom (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citratd human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotrophic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent newazole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 aom and/or P 450 17 were found; 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 aom in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH3 deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 aom and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 aom fadrozole. The compds. show activity in the aforementioned in vivo tests.
 IT 157058-44-1P 157058-45-2P 157058-46-3P 157058-47-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and evaluation ofazole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)
 RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3
 CMF C15 H18 N2 O


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CH 2

CRN 144-62-7

CHF C2 H2 O4



L4 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:97011 CAPLUS
 DOCUMENT NUMBER: 124:260928
 TITLE: Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety
 AUTHOR(S): Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko; Kondo, Kigen; Hamanaka, Nobuyuki
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Heterocycles (1996), 42(2), 517-23
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Structural modification of [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(2-benzhydryloxyiminopentyl)-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid], previously identified as a PGI2 agonist without a PG skeleton, was examd. Such analogs were for example, [[6-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid or [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid. Conversion of the oxime moiety in [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid to a pyrazole led to [[6-[[4-(diphenylmethyl)-1H-pyrazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(4-benzhydrylpyrazolyl)methyl]-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid] which strongly inhibited ADP-induced aggregation of human platelets in vitro.

IT 150559-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of [[[[[phenylmethoxy]imino]alkyl]naphthalenyl]oxy]acetate analogs as nonprostanoid prostacyclin mimetics)

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:827732 CAPLUS
 DOCUMENT NUMBER: 124:202093
 TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV. [Erratum to document cited in CA123:198689]
 AUTHOR(S): Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K.
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2179
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The errors were not reflected in the abstr. or the index entries.

IT 150559-29-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PGI2 agonist activity of (Erratum))

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:612212 CAPLUS
 DOCUMENT NUMBER: 123:198691
 TITLE: Medetomidine analogs as .alpha.-adrenergic agonists
 AUTHOR(S): Amemiya, Yoshiya; Hus, Fulian; Shams, Gamal; Feller, Dennis R.; Venkataraman, B. V.; Patil, Popat N.; Miller, Duane D.
 CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 403-10
 CODEN: EJPSBZ; ISSN: 0301-5068
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 123:198691


AB Recently, it has been reported that medetomidine is a new 4-substituted imidazole analog possessing selective and potent .alpha.2-adrenergic properties. It has been shown that it reduces blood pressure, heart rate and saliva secretion. At the present time is sedative and hypotensive effects seem to be manifest in the same dose range. We have initiated a program to see if it is possible to sep. these activities with analogs of medetomidine. The initial studies have been directed at procedures for the conversion of the imidazolines, a common structure of .alpha.-adrenergic drugs, to the corresponding imidazoles. It was found that 2-substituted and 2,4-disubstituted imidazolines can easily be converted into imidazoles using 10% Pd/C in refluxing toluene, while in some instances there are some difficulties with the conversion of 4-substituted imidazolines to the imidazoles. The synthesis of 1- or 2-(2-or 4-imidazolylmethyl)naphthalene analogs of medetomidine are also described.

IT 137967-88-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of 4-substituted imidazoles)

RN 137967-88-5 CAPLUS

CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:612188 CAPLUS
 DOCUMENT NUMBER: 123:111932
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs of .alpha.- and .beta.-naphthalene
 AUTHOR(S): Amemiya, Yoshiya; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl
 CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 91-112
 CODEN: EJPSBZ; ISSN: 0301-5068
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Seven analogs of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1- (aorta) and .alpha.2- (platelet) activities. The analogs were composed of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either an .alpha.- or .beta.-naphthalene ring system. In general the .alpha.-naphthlene analogs were found to be the most potent inhibitors of platelet aggregation. .alpha.-Naphthalene analogs were partial agonists while the .beta.-naphthalene analogs were antagonists in .alpha.1-adrenergic system (aorta).

IT 137967-82-9P 166034-65-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-82-9 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 166034-65-7 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 137967-88-5
 CMF C15 H14 N2

L4 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:598392 CAPLUS
 DOCUMENT NUMBER: 123:198689
 TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV
 AUTHOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Nagao, Yuuki; Torisu, Kazuhiko; Tokumoto, Hidekado; Kondo, Kigen
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1083-6
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB The synthesis and biol. evaluation of a novel series of di- or tetrahydronaphthalen-5-oxyacetic acid derivs. with a 4-benzhydrylpyrazolyl group is described. Among these compds., I has been identified as a highly potent PGI2 agonist with an exceptionally long in vivo duration of action.


IT 150359-29-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PGI2 agonist activity of)

RN 150359-29-8 CAPLUS
 CN Acetic acid, [(6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)




HO2C-CH2-O

L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 144-62-7
 CMF C2 H2 O4




IT 137967-88-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-88-5 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:513524 CAPLUS
 DOCUMENT NUMBER: 122:265379
 TITLE: Preparation of (cyanobenzyl)azole derivatives as aromatase inhibitors
 INVENTOR(S): Shibata, Tomoyuki; Sugimura, Yukio; Tanzawa, Kazuhiko; Takahashi, Masaaki; Kobayashi, Tomowo; Mitsuhashi, Yoshihiro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408973	A1	19940428	WO 1993-JP1509	19931020
W: AU, CA, CZ, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9352855	A1	19940509	AU 1993-52855	19931020
JP 06263742	A2	19940920	JP 1993-261438	19931020
PRIORITY APPLN. INFO.:				
JP 1992-283177 19921021				
WO 1993-JP1509 19931020				
OTHER SOURCE(S): MARPAT 122:265379				
GI				



I




II




III

AB The title compds. (I; R1 = imidazolyl, triazolyl or tetrazolyl each of which may be substituted by Me and/or Et; R2 = naphthyl, phenanthryl or anthryl each of which may be substituted by substituent(s) selected from C1-4 alkyl, C1-4 alkoxy, C1-6 acyloxy, arom. acyloxy, OH, trialkyl, C1-4 acylamino, alkoxyalkoxy, alkoxyacyloxy, and trialkylsilyloxy; R3 = H, Me, cyano), useful for the treatment of breast cancer, are prepd. Thus, 2-bromo-6-methoxynaphthalene was treated with BuLi in hexane and THF at

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 -78.degree. followed reaction with a soln. of p-cyanobenzaldehyde in THF at -78.degree. gave p-cyano-.alpha.-(6-methoxynaphthalen-2-yl)benzyl alc. which was stirred with SOCl₂ in CH₂Cl₂ at room temp. for 1 h to give p-cyano-.alpha.-(6-methoxynaphthalen-2-yl)benzyl chloride. The latter chloride was dissolved in MeCN and refluxed with imidazole overnight to give, after silica gel chromatog. and acidification with HCl, title compd. (II.HCl) which in vitro showed IC₅₀ of 3.7 nM against aromatase. Hard capsule, tablet, injection and suspension formulations contg. (p-cyanobenzyl)tetrazole deriv. (III.HCl) were described.
 IT 162573-42-4P 162573-46-8P 162573-58-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (cyanobenzyl)azole deriv. as aromatase inhibitor and anticancer agent for breast cancer)
 RN 162573-42-4 CAPLUS
 CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 162573-46-8 CAPLUS
 CN Benzonitrile, 4-(1H-imidazol-4-yl-9-phenanthrenylmethyl)- (9CI) (CA INDEX NAME)




RN 162573-58-2 CAPLUS
 CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:534112 CAPLUS
 DOCUMENT NUMBER: 121:134112
 TITLE: Preparation of imidazolymethylenetetralones and analogs as aromatase inhibitors
 INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton
 PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130	A 19921006
			WO 1993-JP1433	W 19931006

OTHER SOURCE(S): MARPAT 121:134112
 GI




AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxy carbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H₂SO₄ was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolymethylene)-1-tetralone (II). II in vitro showed IC₅₀ of 0.260 .mu.M against aromatase.
 IT 157058-44-1P 157058-45-2P 157058-46-3P
 157058-47-4P 157058-52-1P 157058-53-2P
 157058-54-3P 157058-55-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as aromatase inhibitor)
 RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl


L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)






RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)





RN 157058-52-1 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-

L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(9CI) (CA INDEX NAME)RN 157058-54-3 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)RN 157058-55-4 CAPLUS
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:671157 CAPLUS
DOCUMENT NUMBER: 119:271157
TITLE: Fused benzeneoxycetic acid derivative PGI2 receptor agonists
INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 110 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 548949	A2	19930630	EP 1992-121898	19921223
EP 548949	A3	19931006		
EP 548949	B1	19970917		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
JP 05178832	A2	19930720	JP 1991-360502	19911227
JP 07025854	A2	19950127	JP 1992-209587	19920714
US 5461045	A	19951024	US 1992-912999	19920714
CA 2073917	AA	19940116	CA 1992-2073917	19920715
CA 2085844	AA	19930628	CA 1992-2085844	19921218
AT 158282	E	19971015	AT 1992-121898	19921223
ES 2108076	T3	19971216	ES 1992-121898	19921223
US 5389666	A	19950214	US 1992-997492	19921228
JP 07145057	A2	19950606	JP 1992-360608	19921228
US 5589496	A	19961231	US 1994-334395	19941103
US 5849919	A	19981215	US 1996-722456	19960927
US 5962439	A	19991005	US 1998-168424	19981007
PRIORITY APPLN. INFO.:			JP 1991-360502	19911227
			JP 1992-209587	19920714
			US 1992-997492	19921228
			US 1994-334395	19941103
			US 1996-722456	19960927

OTHER SOURCE(S): MARPAT 119:271157

GI For diagram(s), see printed CA Issue.

AB The title compds. I (A = (un)substituted heterocyclyl; B = alkylene, alkenylene; ring D = carbocyclic ring; R1 = HO, C1-12 alkoxy, (un)substituted amino), which demonstrate PGI2 receptor agonist activity and are useful in the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer, or hypertension (no data), are prepd. and I-contg. formulations presented. Thus, pyrazole deriv. II was prepd. which demonstrated 50% inhibitory concn. against human blood platelet aggregation of 0.043 .mu.M in human blood-derived. platelet-rich plasma.

IT 150558-87-5 150559-29-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(PGI2 receptor agonist activity of)

RN 150558-87-5 CAPLUS

CN Acetic acid, [[5,6,7,8-tetrahydro-6-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:649949 CAPLUS
DOCUMENT NUMBER: 119:249949
TITLE: Preparation of imidazole derivatives as interleukin 1 inhibitors and antiphlogistics
INVENTOR(S): Ueno, Yoshihide; Masumori, Hiroaki; Saji, Kitao
PATENT ASSIGNEE(S): Sumitomo Pharma, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JXXXXF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155882	A2	19930622	JP 1991-348294	19911203
PRIORITY APPLN. INFO.:			JP 1991-348294	19911203

OTHER SOURCE(S): MARPAT 119:249949


GI For diagram(s), see printed CA Issue.

AB The title derivs. I (A = lower alkylene; M = arom. hydrocarbon ring, thiophene; D = O, CO, CH(OR5), C(:NOR5), CH[N(R5)2], NR5, single bond; R1 = H, halo; R2 = lower alkyl or alkenyl, (un)substituted Ph, (un)substituted cycloalkyl, (un)substituted thienyl; R3 = N-contg. heterocyclyl; R4, R5 = H, lower alkyl; when D is single bond then R2 is lower alkyl) or their acid salts are prepd. as interleukin 1 inhibitors and antiphlogistics. A mixt. of 3-(2-fluoro-4-biphenyl)-1-(4-pyridylcarbonyl)amino-2-butanone (prepd. from fluorobipropen in 4 steps), and NH4Ac was heated at 140-150.degree. for 4 h to give 44% 4-(1-(2-fluoro-4-biphenyl)ethyl)-2-(4-pyridyl)imidazole-HCl. I inhibited growth of interleukin 1.

IT 150972-40-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as interleukin 1 inhibitor and antiphlogistics)


RN 150972-40-0 CAPLUS

CN 2-Naphthalenol, 6-[1-[2-(4-pyridinyl)-1H-imidazol-4-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:106173 CAPLUS
 DOCUMENT NUMBER: 116:106173
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs
 AUTHOR(S): Amemiya, Yoshiya; Hong, Seoung S.; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl; Feller, Dennis R.; Hsu, Fu Lian; Miller, Duane D.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Journal of Medicinal Chemistry (1992), 35(4), 750-5
 CODEN: JMCHAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Analogs I-III (R = 1-naphthyl, 2-naphthyl; R1 = H, Me) of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1 (aorta) and .alpha.2 (platelet) activities. In general the 1-naphthalene analogs were the most potent inhibitors of epinephrine-induced platelet aggregation. Of considerable interest was the fact that I-III (R = 1-naphthyl) were antagonists in an .alpha.1-adrenergic system (aorta). Thus, appropriately substituted naphthalene analogs of medetomidine and naphazoline provide a spectrum of .alpha.1-agonist, .alpha.1-antagonist, and .alpha.2-antagonist activity.


IT 137967-82-9P 137967-88-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and adrenergic activity of)
 RN 137967-82-9 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 137967-88-5 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:15364 CAPLUS
 DOCUMENT NUMBER: 116:15364
 TITLE: Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets
 AUTHOR(S): Venkataraman, B. V.; Shams, G.; Hamada, A.; Amemiya, Y.; Tantishaiyakul, V.; Hsu, F.; Fashempour, J.; Romstedt, K. J.; Miller, D. D.; et al.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1991), 344(4), 454-63
 CODEN: NSAPCC; ISSN: 0028-1298
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Potencies of new arom. substituted fluoro or iodo analogs of catecholimidazoline (I) on functional responses in rat aorta (.alpha.1) and platelets (.alpha.2) were quantified. When compared either on the basis of EC50 or the disocn. const. (KA), 5-fluorocatecholimidazoline was as potent as the ref. .alpha.1-adrenoceptor agonist, phenylephrine in the vascular tissue. The max. contraction of aorta produced by the fluoro analog was, however, 17% higher than that of phenylephrine. The time required for 1/2 relaxation of the tissue after 5-fluoro hydroxy imidazoline was at least twice as long as that of the phenylephrine. The catechol moiety as well as fluorine substitution at the crit. 5-position of the arom. ring is essential for higher .alpha.1 adrenoceptor-mediated potency. As compared to the fluoro analogs, the adrenoceptor-mediated potencies of iodo-analogs were relatively weak on vascular tissue. Naphazoline and its analogs were partial agonists on vascular tissue with disocn. consts. which ranged from 110 to 2600 nmol/L. Imidazole analogs (II, R = naphthyl or xylene), were generally less potent agonist than the imidazolines by one order of magnitude. The vascular effects of all agonists were competitively blocked by prazosin with KB values which ranged from 0.04 to 0.48 nmol/L. Since the variation in KB values were within normal limits, the action of new imidazolines on rat aorta appears to be mediated mainly by the activation of the .alpha.1-adrenoceptor. Prazosin 10 nmol/L abolished the vascular response of some partial agonists. This indicates a slightly different mode of interaction of agonists with the transduction process. Carbon 4-substituted imidazolines produced little or no .alpha.1 adrenoceptor-mediated intrinsic activity, but competitive receptor blocking potency was comparable to that of phentolamine. Medetomidine was a partial agonist on the rat aorta with a KA of 260 nmol/L. When investigated as a blocker, the KB of medetomidine against phenylephrine was approx. 5600 nmol/L. The variation in the latter value was high. In acetylsalicylic acid-treated human platelets, the .alpha.2-adrenoceptor-mediated aggregatory effect of all fluoro analogs was weak. Iodo or naphazoline analogs did not initiate platelet

L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 aggregation but blocked the aggregation induced by epinephrine. The affinity of naphazoline for the .alpha.2-adrenoceptor was 1100 nmol/L. The IC50 of medetomidine for platelet anti-aggregatory effect was 3300 nmol/L, which compares favorably with other imidazoline type of blockers of platelet aggregations. Sympathomimetic vasoconstrictor actions and platelet aggregation effects of these compds. can be disocd. Some vasoconstrictors were antiaggregatory. The structure-activity relationships of the two receptor systems, namely rat aorta (.alpha.1) and platelets (.alpha.2), are discussed.
 IT 137967-88-5
 RL: BIOL (Biological study) (.alpha.-adrenoceptors of aorta and human platelets interaction with, structure in relation to)
 RN 137967-88-5 CAPLUS
 CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:623482 CAPLUS
DOCUMENT NUMBER: 115:223482
TITLE: Use of 5-HT₃ receptor antagonists for treatment of panic disorders, agoraphobia, or obsessive compulsive disorders
INVENTOR(S): Azcona, Alberto
PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H., Austria; Sandoz-Patent-G.m.b.H.; Sandoz A.-G.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012569	A1	19901101	WO 1990-EP540	19900406
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2031214	AA	19901022	CA 1990-2031214	19900406
AU 9054158	A1	19901116	AU 1990-54158	19900406
AU 631632	B2	19921203		
EP 422154	A1	19910417	EP 1990-905482	19900406
EP 422154	B1	19931201		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03505881	T2	19911219	JP 1990-505770	19900406
JP 06069963	B4	19940907		
AT 97803	E	19931215	AT 1990-905482	19900406
ES 2061024	T3	19941201	ES 1990-905482	19900406
ZA 9003015	A	19911224	ZA 1990-3015	19900420
US 5530008	A	19960625	US 1994-187413	19940124
PRIORITY APPLN. INFO.:			GB 1989-9147	19890421
			GB 1989-16602	19890720
			EP 1990-905482	19900406
			WO 1990-EP540	19900406
			US 1990-635156	19901219


AB 5-HT₃ receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders. Formulations for tablets, i.v. solns. and capsules are presented.

IT 135716-73-3

RL: BIOL (Biological study)
(5-HT₃ receptor antagonist)

RN 135716-73-3 CAPLUS

CN 1(2H)-Phenanthrene, 3,4-dihydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]-
(9CI) (CA INDEX NAME)




L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:198377 CAPLUS
DOCUMENT NUMBER: 112:198377
TITLE: Preparation and formulation of imidazole derivatives as 5-HT₃ receptor antagonists
INVENTOR(S): North, Peter Charles; Oxford, Alexander William; Coates, Ian Harold
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 336759	A1	19891011	EP 1989-303415	19890406
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02049772	A2	19900220	JP 1989-87841	19890406
US 5116984	A	19920526	US 1989-333967	19890406
PRIORITY APPLN. INFO.:			GB 1988-8085	19880407
			GB 1988-8086	19880407

OTHER SOURCE(S): MARPAT 112:198377

GI



AB Title compds. I (R₁, R₂ = H, halo, HO, C1-4 alkoxy, C1-4 alkyl, C1-4 alkylthio, R₃R₄N, R₃, R₄ = H, C1-4 alkyl, R₃R₄N = satd. 5-7-membered ring; A = CH, N; Im = substituted imidazolyl; n = 1-3) and physiol. acceptable salts and solvates thereof, potent and selective antagonists of 5-HT₃ receptors and useful, e.g., in treatment of psychotic disorders, anxiety, and nausea and vomiting (no data), are prepd. 1,2-Dihydro-3-[[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl)methylene]-4(3H)-phenanthrene (prepn given) was dehydrogenated over Pd/C to give I (R₁, R₂ = H; A = CH; Im = 5-methylimidazol-4-yl; n = 2) which was converted to the maleate. Tablet and injection formulations were given.

IT 126737-65-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as 5-HT antagonist)

RN 126737-65-3 CAPLUS


CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRW 126737-65-3

CMF C19 H18 N2 O

L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 126737-65-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as HT₃-receptor antagonist)

RN 126737-65-3 CAPLUS


CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-
(9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1990:139033 CAPLUS
 DOCUMENT NUMBER: 112:139033
 TITLE: Preparation of imidazole derivatives as drugs
 INVENTOR(S): Kihara, Noriaki; Tomino, Ikuo; Tan, Hiroaki; Takei, Mitsusachi
 PATENT ASSIGNEE(S): Mitsui Petrochemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01242571	A2	19890927	JP 1988-65731	19880322
PRIORITY APPLN. INFO.: JP 1988-65731			19880322	
OTHER SOURCE(S): MARPAT 112:139033				

GI




AB The title derivs. I or II (R1 = H, Ph; R2-R5 = H, OH, lower alkyl, lower alkoxy, lower alkylamino, halo; R2-R5 may be bonded to from rings; R6, R7 = H, lower alkyl, halo; X = O, S), useful as cerebral function improvers, antihypertensives, diuretics, etc. (no data), are prepd. by acid-catalyzed reaction of (hydroxymethyl)imidazoles III or their acid salts with benzenes IV or 5-membered heterocycle V. Thus, aq. III.HCl (R1 = H) was treated with 1,3,5-C6H3Me3 and 4-MeC6H4SO3H at 170.degree. for 7 h to give 761 I (R1 = R2 = H, R3-R5 = 2,4,6-Me3).

IT 125883-69-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as drug)

RN 125883-69-4 CAPLUS



CN 1H-Imidazole, 4-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1979:168771 CAPLUS
 DOCUMENT NUMBER: 90:168771
 TITLE: Photochemical reactions. Photochemistry of N-acylimidazoles. V. Photolysis of the N-acylimidazoles of dehydroabiatic acid and of 13-deisopropyl-10-epi-dehydroabiatic acid
 AUTHOR(S): Iwasaki, Shigeo
 CORPORATE SOURCE: Org.-Chem. Lab., ETH, Zurich, Switz.
 SOURCE: Helvetica Chimica Acta (1978), 61(8), 2843-50
 CODEN: HCACAV; ISSN: 0018-019X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

L4 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB Irradn. of I gave no Type II elimination, but gave II and III by migration of the imidazolylcarbonyl group, probably via a cyclobutanol intermediate. Similarly, irradn. of IV gave only a small amt. of Type II fragmentation, the main products being derived from gamma.-H abstraction.

IT 69634-29-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 69634-29-3 CAPLUS


CN Methanone, 1H-imidazol-4-yl[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1973:515495 CAPLUS
 DOCUMENT NUMBER: 79:115495
 TITLE: Synthesis of small molecule catalysts. Model for the active site of ribonuclease-A
 AUTHOR(S): Algieri, Aldo A.
 CORPORATE SOURCE: Cornell Univ., Ithaca, NY, USA
 SOURCE: (1973) 116 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 73-14,715
 From: Diss. Abstr. Int. B 1973, 33(12) (Pt. 1), 5722
 DOCUMENT TYPE: Dissertation
 LANGUAGE: English
 AB Unavailable
 IT 49738-45-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (as model for the active site of ribonuclease A)
 RN 49738-45-6 CAPLUS
 CN 1H-Imidazole-4-ethanamine, N-[[3-(1H-imidazol-4-ylmethyl)-1-naphthalenyl)methyl]-, conjugate diacid (9CI) (CA INDEX NAME)



● 2 H⁺

L4 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1972:501463 CAPLUS
 DOCUMENT NUMBER: 77:101463
 TITLE: Voges-Proskauer reaction. II. Structure of a pigment from the diacetyl reaction of 1-benzyl-1-methylguanidine
 AUTHOR(S): Nishimura, Tamio; Yamazaki, Chiji; Ueno, Tetsuro; Kitajima, Shinichi; Ishige, Koichi
 CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Tokyo, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1972), 45(6), 1782-5
 CODEN: BCSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A pigment formed by the reaction of 1-benzyl-1-methylguanidine was isolated as reddish purple prisms. The reduced pigment was colorless and rapidly converted back to the original pigment on exposure to the air. On the basis of ir, NMR, and mass spectral evidence, the structures of the pigment and the reduced form were established to be 2-(N-benzyl-N-methylamino)-4-methyl-5-(1-oxo-1,2-dihydro-2-naphthylidenemethyl)imidazole and 5-(1-hydroxy-2-naphthylmethyl)imidazole, resp.
 IT 37842-56-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 37842-56-1 CAPLUS
 CN 1-Naphthalenol, 2-[[5-methyl-2-(methyl(phenylmethyl)amino)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

150.78

299.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-20.83

-20.83

STN INTERNATIONAL LOGOFF AT 07:05:47 ON 03 FEB 2003

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:358249 CAPLUS

DOCUMENT NUMBER: 125:75343

TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 aro, P450 17 and P450 TxA2

AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.

CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261

CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: VCH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 aro (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citratated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotropic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 aro and/or P 450 17 were found; 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 aro in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH3 deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 aro and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 aro fadrozole. The compds. show activity in the aforementioned in vivo tests.


IT 157058-44-1P 157058-45-2P 157058-46-3P
157058-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-52-1P 157058-53-2P 157058-55-4P
178880-06-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-52-1 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-53-2 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3


CMF C15 H18 N2 O



CM 2

CRN 144-62-7

CMF C2 H2 O4



L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:534112 CAPLUS

DOCUMENT NUMBER: 121:134112

TITLE: Preparation of imidazolylmethylenetetralones and analogs as aromatase inhibitors

INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton

PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130	A 19921006
			WO 1993-JP1433	W 19931006
OTHER SOURCE(S):			MARPAT 121:134112	
GI				




AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxy carbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H₂SO₄ was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro showed IC₅₀ of 0.260 .mu.M against aromatase.

IT 157058-44-1P 157058-45-2P 157058-46-3P
157058-47-4P 157058-52-1P 157058-53-2P
157058-54-3P 157058-55-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as aromatase inhibitor)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




P^1 is oxo
 R^2 & R^3 form unsaturated ring ✓
 $R_6 = H$
 $S=O$
 $T=O$


RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy-
 (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy-
 (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
 (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA
 INDEX NAME)






RN 157058-53-2 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 157058-54-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)

